Paper Details

  1. Home
  2. Paper Details

Single-Dose Zoliflodacin (ETX0914) for Treatment of Urogenital Gonorrhea.

Author: BatteigerByron E, HookEdward W, JohnsonShacondra M, KwakHannah, LawrenceKenneth, LongJill, MarrazzoJeanne, MuellerJohn, SeñaArlene C, TaylorStephanie N, WierzbickiMichael R

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.

Overview

This multicenter, phase 2 trial evaluated zoliflodacin for the treatment of uncomplicated gonorrhea. The majority of uncomplicated urogenital and rectal gonococcal infections were successfully treated with oral zoliflodacin, but this agent was less efficacious in the treatment of pharyngeal infections.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Antibiotic-resistant Neisseria gonorrhoeae has prompted the development of new therapies. Zoliflodacin is a new antibiotic that inhibits DNA biosynthesis. In this multicenter, phase 2 trial, zoliflodacin was evaluated for the treatment of uncomplicated gonorrhea. METHODS: We randomly as...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1056/NEJMoa1706988

データ提供：米国国立医学図書館（NLM）

A New Weapon in the Fight Against Gonorrhea: Single-Dose Zoliflodacin

Imagine the desert as a battlefield, where the enemy, antibiotic-resistant Neisseria gonorrhoeae, is becoming increasingly difficult to defeat. This study explores a new weapon in the fight against this formidable foe: zoliflodacin, a novel antibiotic that inhibits DNA biosynthesis. It's like discovering a hidden weapon in an ancient tomb, a powerful tool that could tip the scales in the battle against this resilient enemy.

A Single Dose, a Powerful Impact: Zoliflodacin's Efficacy

The study found that a single dose of zoliflodacin was highly effective in treating uncomplicated urogenital gonorrhea. This is like a swift and decisive strike that can quickly vanquish the enemy. The study also found that zoliflodacin was less effective in treating pharyngeal infections, highlighting the need to continue research and explore ways to enhance its efficacy against this specific type of infection.

Protecting Our Health: The Fight Against Antibiotic Resistance

This study provides encouraging evidence for the potential of zoliflodacin to combat antibiotic-resistant gonorrhea. It's like finding a new source of water in a parched desert, offering hope for a sustainable future. However, it's crucial to use antibiotics responsibly to avoid further resistance. This is like using water resources carefully to prevent depletion and ensure the long-term health of the desert ecosystem.

Dr.Camel's Conclusion

This study is a significant step forward in the fight against antibiotic-resistant gonorrhea. It's like a beacon of hope shining in the desert of antibiotic resistance. But it's important to remember that this is just one battle in a larger war. We must continue to invest in research and development to find new ways to combat this formidable foe.

Date :
  1. Date Completed 2018-11-16
  2. Date Revised 2021-12-04
Further Info :

Pubmed ID

30403954

DOI: Digital Object Identifier

10.1056/NEJMoa1706988

Related Literature

Article Analysis
・Effects of cefotaxime injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.